| HOME >> BIOLOGY >> TECHNOLOGY |
BALTIMORE, May 6, 2011 /PRNewswire/ -- Stenting is safe and effective and superior to balloon angioplasty for treatment of venous stenosis in patients with deep vein thrombosis (DVT), according to results from EVISTA-DVT, presented today as a Late-Breaking Clinical Trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions in Baltimore.
EVISTA-DVT focused on patients with blocked veins who had received clot-buster drug therapy (thrombolysis). Researchers found stenting was more effective than balloons alone at restoring and maintaining blood flow through the thigh veins.
"We are encouraged by these study results," said Mohsen Sharifi, MD, FSCAI, director of Arizona Cardiovascular Consultants and adjunct professor at A.T. Still University in Mesa, Ariz. "For patients with DVT, stenting is a viable option, as demonstrated by the success rates for patients studied in this trial."
DVT affects approximately 350,000 to 600,000 Americans each year. Blood clots form in a vein in the lower leg and thigh. If left untreated, the clot can block blood flow through the vein. If the clot moves through the bloodstream, it can get stuck in the lungs leading to pulmonary embolism and possibly death. It is estimated at least 100,000 deaths may be directly or indirectly related to DVT and blood clots that travel to the lungs. Inserting a stent – a tiny mesh tube – opens up the blockage that may cause future clot formation.
The trial included 141 patients who had initial clot-dissolving drug therapy, but continued to have blockage of their vein. Patients were randomly assigned to further treatment with stenting (71 patients) or balloon venoplasty alone (70 patients) to open up the blocked vein. Every six months researchers checked blood flow through the leg veins using ultrasound.
During a follow-up that averaged 35 months, three patients (4%) in the stent group and seven patients (10%) in the
'/>"/>
| SOURCE Society for Cardiovascular Angiography and Interventions (SCAI) Copyright©2010 PR Newswire. All rights reserved |
Related biology technology :
1. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
2. Reportlinker Adds Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development
3. Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study
4. New Biomarkers Study Could Lead to Better Malaria Vaccine Design
5. Columbia engineering study links ozone hole to climate change all the way to the equator
6. ACT Files European Clinical Trial Application for Phase 1/2 Study Using Embryonic Stem Cells to Treat Macular Degeneration
7. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
8. Scientists recreate brain cells from skin cells to study schizophrenia safely
9. Study finds public relatively unconcerned about nanotechnology risks
10. Newly Published Study Shows Dramatic Reduction in Hospital Acquired Infections
11. Catalysis Foundation for Health Selects BioFortis Labmatrix Database Software for International Tuberculosis Diagnostic Biomarker Study
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |